


## Chemoenzymatic Synthesis of the Morphine Skeleton via Radical Cyclization and a C<sub>10</sub>-C<sub>11</sub> Closure.

Gabor Butora, Tomas Hudlicky,\* Stephen P. Fearnley, Andrew G. Gum, Michele R. Stabile, and Khalil Abboud†

Department of Chemistry, University of Florida, Gainesville, FL 32611-7200

**Abstract:** A short synthesis of a morphinan skeleton has been accomplished. The key steps involve enzymatic dihydroxylation of  $\beta$ -bromoethyl benzene, vinyl and aryl radical cyclizations, and Friedel-Crafts closure of an aziridinium ion or an acid-catalyzed closure of an aldehyde to form the C<sub>10</sub>-C<sub>11</sub> bond.  
 Copyright © 1996 Elsevier Science Ltd


In 1954, Gates<sup>1</sup> reported the first total synthesis of morphine **1** by an ingenious yet simple route, utilizing a  $\beta$ -dihydrothebainone-dihydrothebainone isomerization sequence in order to adjust the C<sub>14</sub> stereocenter. Since Gates's original approach, a total of 16 syntheses have been reported.<sup>2</sup> The majority (nine of them), including the most recent one of Overman,<sup>2b</sup> proceed *via* 1-benzylisoquinoline intermediates, with the crucial step being C<sub>12</sub>-C<sub>13</sub> bond formation. These syntheses are formalized by intercepting Gates's dihydrothebainone (or  $\beta$ -dihydrothebainone) or by producing thebaine. The most efficient routes to date, those of Rice<sup>2c</sup> and Beyerman,<sup>2d</sup> have also used this strategy. Despite a number of attempts, only one successful synthesis (Evans)<sup>2e</sup> utilized a C<sub>10</sub>-C<sub>11</sub> closure late in the synthesis in order to complete the morphinan skeleton, followed by adjustment of stereochemistry at C<sub>14</sub>.



In 1994, Parker reported the full details<sup>2f, g</sup> of a radical cascade approach (published in a preliminary form in 1992)<sup>2h</sup> to racemic **1**. Parallel to Parker's effort, we designed a similar strategy, and during our first-generation approach to the synthesis of enantiomerically pure **1** we also encountered problems with low yields in the radical cascades.<sup>3</sup> In this manuscript, we report the second-generation approach in which both the yields and the stereoselectivity have been addressed.

Our strategy is based on the exploitation of microbial dioxygenase-mediated degradation of toluene, elucidated by Gibson in 1969.<sup>4</sup> In the arene degradation pathway, elimination of catechol dehydrogenase synthesis by mutation of the wild strain yields an organism *Pseudomonas putida* 39/D<sup>4</sup> that converts aromatic compounds to cyclohexadiene *cis*-diols, which accumulate in the fermentation broth. We have taken advantage of this process by converting 2-(2-bromoethyl)bromobenzene **6** to diol **3**.<sup>5</sup> Even though 2-bromo-6-methoxyphenol **4** is directly available via bromination of guaiacol, we have shown that the precursor, catechol **8**, is also accessible from bromobenzene via full biooxidation of bromobenzene (*Pp* TGO2C or *E. coli* JM 109, pDTG602, where both

toluene dioxygenase and catechol dehydrogenase are expressed<sup>6</sup> or partial biooxidation (*Pp* 39/D; Jones oxidation). Exhaustive methylation (MeI/K<sub>2</sub>CO<sub>3</sub>) followed by selective demethylation (TMSI) yields **4**, Scheme 1. In this fashion two of the three fragments required for synthesis are available via biocatalysis; the third, oxazolone **5**,<sup>7</sup> is prepared electrochemically, thus contributing to the environmentally benign nature of the synthesis.




Scheme 1

The chirality, set enzymatically in **3**, is propagated through the synthesis by the directing effects of the *cis*-diol moiety. Diol **3** ( $t_{1/2}$  = one week in CDCl<sub>3</sub> solution) was reduced with diimide (50% yield) in order to minimize the tendency toward aromatization, protected as an acetonide (2,2-dimethoxy propane, methylene chloride, cat. *p*TsOH, 95%), and coupled with oxazolone **5**<sup>7</sup> (39%) to give<sup>8</sup> the precursor to the first radical closure, vinyl bromide **10**. Exposure of this material to Bu<sub>3</sub>SnH and AIBN in refluxing benzene gave a 2:1 mixture of **11a** and **11b** in a combined yield of 89% after deprotection of the acetonide with Dowex 50X8-100 acidic resin in aqueous methanol. <sup>1</sup>H- and <sup>13</sup>C-NMR analysis and nOe, confirmed by x-ray of **11a**,<sup>9</sup> led to the assignment of absolute stereochemistry as shown. As the only center in morphine not subject to facile manipulation is C<sub>9</sub> corresponding to C<sub>1</sub> in isoquinolines **11**, we chose to pursue the route using the more abundant **11a**, leading ultimately to ent-morphinan skeleton.

Diol **11a** was selectively protected with TBDMSOTf (86%) and subjected to Mitsunobu protocol using the monomethyl ether of bromocatechol **4** to yield **12** (94%), which contains all of the carbons for codeine. This material smoothly cyclized to **13** (49%). The combined yields of both ring closures were higher than those of the radical cascade from the first generation, and the second cyclization proceeded stereospecifically giving only the diastereomer **13**. The absolute stereochemistry at C<sub>14</sub> corresponds to that of the enantiomer of  $\beta$ -thebainone. The closure of the free alcohol, derived from **12**, did not affect the absolute stereochemistry<sup>10</sup> of C<sub>14</sub>, and the pentacycle **14** was isolated in 29% yield.

The TBDMS protected pentacycle **13** was reduced with DIBAL to **18** (95%) to furnish the *N*-methyl functionality and to establish the C<sub>10</sub> electrophilic center by mesylation with in situ displacement to **19** (81%). Exposure of **19** to AlCl<sub>3</sub> in benzene gave material whose analysis suggested a mixture of morphinan **20** and the corresponding free phenol<sup>11</sup> resulting from the aluminum-chloride-catalyzed demethylation. To our knowledge this would be the first instance of a direct C<sub>10</sub>-C<sub>11</sub> closure of a compound already containing the furan ring and a

$C_{10}$   $sp^3$ -hybridized center.<sup>12</sup> Poor reproducibility of this reaction on small scale (<5 mg) compelled us to search for alternatives.



Reagents and conditions: (i) DMP, *p*-TSA; (ii) **5**, NaH, DMSO; (iii)  $n\text{Bu}_3\text{SnH}$ , AIBN, benzene, reflux; (iv) Dowex 50X8-100, MeOH,  $\text{H}_2\text{O}$ ; (v) TBDMSTf,  $i\text{Pr}_2\text{EtN}$ , THF,  $-78^\circ\text{C}$ ; (vi) **4**, DEAD,  $n\text{Bu}_3\text{P}$ , THF,  $0^\circ\text{C}$ ; (vii) TBAF, THF; (viii) DIBAL-H,  $\text{CH}_2\text{Cl}_2$ ,  $0^\circ\text{C}$ ; (ix) ClCOCOCl, DMSO,  $\text{Et}_3\text{N}$ ,  $\text{CH}_2\text{Cl}_2$ ,  $-78$  to  $0^\circ\text{C}$ ; (x)  $\text{CF}_3\text{SO}_3\text{H}$ ; (xi) MsCl,  $\text{Et}_3\text{N}$ , THF; (xii)  $\text{AlCl}_3$ , benzene, reflux.

Scheme 2


Reduction of **14** with DIBAL-H followed by a double Swern oxidation yielded the ketoaldehyde **15** (70%), which upon exposure to trifluoromethyl sulfonic acid furnished the  $C_{10}$ -hydroxy morphinan **16** (70%), as evidenced by the appearance of two upfield doublets, ( $\delta$  6.84, 6.68 in benzene- $d_6$  or 6.97, 6.79 in chloroform- $d$ ), corresponding to the aromatic protons of a complete morphinan skeleton.<sup>13</sup> Reduction of **16**, epimerization at  $C_{14}$  based on a known procedure,<sup>14</sup> and demethylation would formalize the synthesis of ent-morphine.

In summary, the synthesis of a complete morphinan skeleton has been accomplished with reasonable stereoselectivity in 13 steps from 2-(2-bromoethyl)bromobenzene. Further refinement of this strategy is currently in progress in our laboratory and will be reported in due course.

**Acknowledgments:** The authors thank Mallinckrodt Chemicals, Inc., and TDC Research, Inc., for funding.

**References and notes:**

- Gates, M.; Tschudi, G. *J. Am. Chem. Soc.* **1952**, *74*, 1109.
  - Gates, M. *J. Am. Chem. Soc.* **1950**, *72*, 228.
  - Gates, M.; Tschudi, G. *J. Am. Chem. Soc.* **1956**, *78*, 1380.
  - Gates, M. *J. Am. Chem. Soc.* **1953**, 4430.
  - Gates, M.; Helg, R. *J. Am. Chem. Soc.* **1953**, *75*, 379.
  - Gates, M.; Tschudi, G. *J. Am. Chem. Soc.* **1950**, *72*, 4839.
- For recent reviews see: Hudlicky, T.; Butora, G.; Fearnley, S.P.; Gum, A.G.; Stabile, M.R. *Studies in Natural Products Chemistry*; Rahman, A., Ed.; Elsevier: Amsterdam, 1996; pp 43–154; Maier, H. In *Organic Synthesis Highlights II*; Waldmann, H., Ed.; VCH: Weinheim, 1995; pp 357–369.
  - Hong, C.Y.; Kado, N.; Overman, L.E. *J. Am. Chem. Soc.* **1993**, *115*, 11028.
  - Rice, K.C. *J. Org. Chem.* **1980**, *45*, 3135.
  - Lie, T.S.; Maat, L.; Beyerman, H.C. *Recl. Trav. Chim. Pays-Bas* **1979**, *98*, 419.
  - Evans, D.A.; Mitch, C.H. *Tetrahedron Lett.* **1982**, *23*, 285–288.
  - Parker, K.A.; Fokas, D. *J. Org. Chem.* **1994**, *59*, 3927.
  - Parker, K.A.; Fokas, D. *J. Org. Chem.* **1994**, *59*, 3933.
  - Parker, K.A.; Fokas, D. *J. Am. Chem. Soc.* **1992**, *114*, 9688.
  - Rice, K.C. *The Chemistry and Biology of Isoquinoline Alkaloids*, Phillipson et al, Ed.; Springer-Verlag: Berlin, 1985; pp 191–203.
- The following sequence was carried out in our laboratories in the natural enantiomer series (ca. 10 % yield):



- Gibson, D.T.; Hensley, M.; Yoshioka, H.; Mabry, T.J. *Biochemistry* **1970**, *9*, 1626.
- Stabile, M.R.; Hudlicky, T.; Meisels, M.L.; Butora, G.; Gum, A. G.; Fearnley, S. P.; Thorpe, A. J.; Ellis, M. R. *Chirality* **1995**, *7*, 556.
- In *E. coli* JM109 (pDTG 602) the catechol dehydrogenase is still synthesized but the expression of enzymes for the next step in the degradation, namely the ortho-scission, has been blocked. See: Zylstra, G. J.; Gibson, D. T. *J. Biol. Chem.* **1989**, *164*, 14940.
- Tavernier, D.; Van Damme, S.; Ricquier, P.; Anteunis, M.J.O. *Bull. Soc. Chim. Belg.* **1988**, *97*, 859.
- The alkylation of oxazolone yielded a substantial amount (55 %) of (3aR,7aS)-5-bromo-2,2-dimethyl-4-vinylbenzodioxol, which, after hydroboration/oxidation (9BBN, H<sub>2</sub>O<sub>2</sub>) and mesylation (MsCl/iPr<sub>2</sub>NEt), was coupled with oxazolone to yield **10**.
- Full x-ray crystallography data will be published in *Acta Cryst.* by Khalil Abboud, University of Florida.
- Work of Gates, Evans, and others suggests that the unnatural absolute stereochemistry at C<sub>14</sub> predominates (or is sterically feasible) when either the C<sub>5</sub>-O bond ( $\beta$ -thebainone) or C<sub>10</sub>-C<sub>11</sub> bonds are disconnected. For recent reference see: Cheng, C.-Y., Hsin, L.-W., Liou, J.-P. *Tetrahedron*, **1996**, *52*, 10935.
- The mass spectrum of the mixture indicated the presence of ions 302.1800 (C<sub>18</sub>H<sub>24</sub>NO<sub>3</sub>,  $\delta$  = 4.4 ppm) and 288.1590 (C<sub>17</sub>H<sub>22</sub>NO<sub>3</sub>,  $\delta$  = 0.9 ppm), corresponding to morphinan **20** and the free phenol derived from its the AlCl<sub>3</sub>-catalyzed demethylation, respectively. This result indicates that a C<sub>10</sub>-C<sub>11</sub> closure is possible with compound containing the complete benzofuran unit.
- Schultz, A.G.; Lucci, R.D.; Napier, J.J.; Kinoshita, H.; Ravichandran, R.; Shannon, P.; Yee, Y.K. *J. Org. Chem.* **1985**, *50*, 217.
- All analytical and spectral data obtained were consistent with the structural assignments.
- Weller, D. D.; Rappoport, H. *J. Med. Chem.* **1976**, *19*, 1171.

(Received in USA 12 September 1996; accepted 13 September 1996)